Therapy Areas: Diabetes
Kodiak Sciences names new Director
20 December 2019 -

Kodiak Sciences Inc (Nasdaq: KOD), a clinical stage biopharmaceutical company specialising in novel therapeutics to treat chronic, high-prevalence retinal diseases, announced yesterday that it has named Taiyin Yang, PhD as a director.

Presently, Dr Yang serves as executive vice president, Pharmaceutical Development and Manufacturing at Gilead Sciences, Inc. She joined Gilead in 1993.

Victor Perlroth, MD, chief executive officer of Kodiak Sciences, said, 'Dr Yang joins our board in a growth phase for Kodiak as we pursue our 2022 Vision for KSI-301 in retinal vein occlusion, wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy and our anticipated Biologics License Application (BLA) and supplemental BLA submissions. Dr Yang's deep experience with product development, commercial manufacturing and quality operations will be instrumental as we advance KSI-301 and our deepening pipeline of bi-specific and triplet ABC product candidates.'

Login
Username:

Password: